The leading clinical investigators from the European community, the so-called “Mallorca group”, have recently published revised guidelines for the clinical management of Lynch syndrome. Their paper provides an important update on the identification, education and management of Lynch syndrome, but further investigation is still warranted.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Vasen, H. F. et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut http://dx.doi.org/10.1136/gutjnl-2012-304356.
Balmaña, J. et al. Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA 296, 1469–1478 (2006).
Dinh, T. A. et al. Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev. Res. 4, 9–22 (2010).
Järvinen, H. J., Mecklin, J.-P. & Sistonen, P. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 108, 1405–1411 (1995).
Hüneburg, R. et al. Chromocolonoscopy detects more adenomas than white light colonoscopy or narrow band imaging colonoscopy in hereditary nonpolyposis colorectal cancer screening. Endoscopy 41, 316–322 (2009).
Pylvanainen, K. et al. Causes of death of mutation carriers in Finnish Lynch syndrome families. Fam. Cancer 11, 467–471 (2012).
de Vos tot Nederveen Cappel, W. H. et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis. Colon Rectum 45, 1588–1594 (2002).
Parry, S. et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut 60, 950–957 (2010).
Vasen, H. F. et al. Lynch syndrome: how should colorectal cancer be managed? Nat. Rev. Gastroenterol. Hepatol. 8, 184–186 (2011).
Watson, P. et al. Carrier risk status changes resulting from mutation testing in hereditary nonpolyposis colorectal cancer and hereditary breast-ovarian cancer. J. Hum. Genet. 40,591–596 (2003).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Lynch, H., Lynch, P. Update on the clinical management of Lynch syndrome. Nat Rev Gastroenterol Hepatol 10, 323–324 (2013). https://doi.org/10.1038/nrgastro.2013.70
Published:
Issue date:
DOI: https://doi.org/10.1038/nrgastro.2013.70
